Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1) is a key regulator of cellular signaling pathways.
• SHP-1 acts as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (p-STAT3).
• Dysregulation of SHP-1/p-STAT3 signaling is implicated in various malignancies and nonmalignant conditions.

Purpose of the Study:

• To review the multifaceted roles of SHP-1/p-STAT3 signaling in both nonmalignant and malignant contexts.
• To elucidate the cross-talk between SHP-1/p-STAT3 and other critical cellular pathways.
• To discuss the therapeutic potential of targeting SHP-1/p-STAT3 signaling in cancer treatment.

Main Methods:

• This review synthesizes existing literature on SHP-1/p-STAT3 signaling.
• It examines preclinical and clinical studies related to SHP-1/p-STAT3.
• The review highlights research on novel inhibitors and combination strategies targeting this pathway.

Main Results:

• SHP-1/p-STAT3 signaling plays a critical role in tumor development and progression.
• Cross-talk with other pathways influences the biological impact of SHP-1/p-STAT3.
• Inhibitors targeting SHP-1/p-STAT3 show promise in preclinical anticancer studies.

Conclusions:

• SHP-1/p-STAT3 signaling is a significant therapeutic target in oncology.
• Targeting this pathway offers potential for novel anticancer strategies.
• Further research into combined therapies involving SHP-1/p-STAT3 inhibitors is warranted.